|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:OncoOne
Kuur Therapeutics
|
|
gptkbp:CEO
|
gptkb:Dr._Johnson_Lau
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:Canada
gptkb:United_States
Europe
Phase 1
Phase 2
Phase 3
collaborative studies
observational studies
longitudinal studies
solid tumors
randomized trials
hematological malignancies
|
|
gptkbp:collaborations
|
gptkb:Roswell_Park_Comprehensive_Cancer_Center
gptkb:University_of_Buffalo
|
|
gptkbp:employeeCount
|
over 200
|
|
gptkbp:focus
|
cancer treatment
|
|
gptkbp:founded
|
2003
|
|
gptkbp:founder
|
gptkb:R._Scott_Greer
|
|
gptkbp:funding
|
grants
venture capital
public offerings
|
|
gptkbp:headquarters
|
gptkb:Buffalo,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Athenex
|
|
gptkbp:market
|
gptkb:Latin_America
gptkb:North_America
gptkb:Asia-Pacific
Europe
|
|
gptkbp:mission
|
improve patient outcomes
advance cancer therapies
|
|
gptkbp:partnerships
|
gptkb:Celgene_Corporation
gptkb:Bristol-Myers_Squibb
gptkb:Sorrento_Therapeutics
|
|
gptkbp:patentCitation
|
therapeutic uses
delivery methods
drug formulations
|
|
gptkbp:patentType
|
gptkb:KX2-391
Oral Paclitaxel
|
|
gptkbp:products
|
gptkb:KX2-391
TCR-T cell therapy
Oral Paclitaxel
|
|
gptkbp:research_areas
|
oncology
hematology
infectious diseases
immunology
|
|
gptkbp:research_focus
|
targeted therapies
drug delivery systems
immunotherapy
chemotherapy agents
|
|
gptkbp:sells
|
gptkb:ATNX
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:ATNX
|
|
gptkbp:vision
|
leading biopharmaceutical company
|
|
gptkbp:website
|
www.athenex.com
|